Cambridge, United States
Concerto Biosciences, founded in 2020, stands at the forefront of integrating big data and biotechnology to unlock vast microbial potentials. Operating out of the United States, the company capitalizes on its slogan, "It takes a village — of microbes." By harnessing its proprietary kChip platform, Concerto Biosciences effectively measures and maps microbial communities to generate over 40 million combinations, optimizing their AI model (kAI). This leads to the development of innovative applications in skin health, women’s health, and food science.
Their first promising outcome in skin health includes ENS-002, a live biotherapeutic aimed at eczema, and CB-002, a postbiotic consumer product. The recent $24.54 million Series A investment in March 2022 speaks volumes about investor confidence, with backing from MassVentures, Horizons Ventures, Safar Partners, Excelestar Ventures, and the MERL Ventures Fund. Concerto Biosciences' strategic partnerships with global organizations further underline its commitment to pioneering solutions that satisfy the evolving needs of the 21st century.
